MAGEA4 and colorectal carcinoma: Anti-MAGEA4 was found to have best diagnostic potential for detecting early stage CRC and advanced adenomas, with sensitivities of 11% (95% CI, 4−28%) and 12% (95% CI, 7−20%), respectively, at a specificity of 96%.